Human cDNA microarray system for researchers seeking access to premium gene content as well proprietary detection technology for ultra-sensitive gene expression results
PerkinElmer Life Sciences has announced the availability of the Micromax human cDNA microarray system II-TSA, a complete system incorporating gene content from Incyte Genomics.
This new microarray offering features sequence-verified human drug target genes mined from Incyte Genomics's LifeSeq Gold database, as well as PerkinElmer Life Sciences's ultra-sensitive TSA amplification technology.
The human cDNA microarray system II-TSA is ideal for any researcher seeking access to premium gene content as well as PerkinElmer Life Sciences's proprietary detection technology for ultra-sensitive gene expression results. "With Incyte Genomics, PerkinElmer Life Sciences can now offer its customers a microarray solution from the largest collection of gene content currently available," said Paul Gillyon, vice president and general manager of biomics at PerkinElmer Life Sciences.
"Customers can now depend on PerkinElmer Life Sciences not only for cutting-edge microarray technology, but also as a provider of extensive gene content." The Micromax human cDNA microarray system II-TSA is equipped with two slides containing approximately 5000 genes per slide, two practice/control microarrays, six coverslips, two plastic templates and a TSA labelling and detection system. PerkinElmer Life Sciences customers also have the option of purchasing the Micromax microarray: human cDNA II, which includes two slides pre-spotted with the same Incyte Genomics content, but which does not include practice microarrays or the TSA system. This product is ideal for researchers who prefer to use their own labelling and detection reagents.
